Abstract: Advances in the understanding of the mechanisms accounting for the elevation of arterial pressure in essential hypertension suggest that there is value in assessing the relative contribution of hemodynamic factors in tailoring specific therapies to control arterial pressure. The non-invasive method of impedance cardiography (ICG) to measure hemodynamic abnormalities in hypertensive patients has emerged as a valuable adjuvant in the decisionmaking process of selecting antihypertensive agents. The technique is both accurate and reproducible in delineating the hemodynamic mechanisms of hypertension, comparing ageand gender-related changes in hemodynamics, detecting the presence of left ventricular dysfunction, and demonstrating clinically significant improvement in blood pressure control using ICG-guided therapy.
Introduction
Hypertension affects over 65 million Americans [Fields et al. 2004] and remains the most common reason that an adult in the United States visits a physician for ongoing care [Cherry and Woodwell, 2002] . Despite a large number of effective antihypertensive medications, there have been only modest improvements in blood pressure (BP) control over the last few decades [Wang and Vasan, 2005] . Efforts to improve hypertension management have been hampered by a number of factors, including the reliance on BP levels measured only periodically in doctors' offices, suboptimal therapy, patient noncompliance due to cost of therapy and adverse effects of medications, and the reluctance of physicians to intensify therapy despite elevated BP readings, a phenomenon termed clinical inertia [Garg et al. 2005; Okonofua et al. 2006; Phillips et al. 2001] .
Although guidelines have been proposed that improve risk stratification through the identification of multiple cardiovascular (CV) risk factors [Mancia et al. 2007a; Mancia et al. 2007b] , there has been only modest progress in the medical management of those with hypertension at highest risk of CV morbidity and mortality [Wang [Bestermann et al. 2005; Houston et al. 2005] . This scoring system allows greater refinement of risk assessment than do other CV risk tools because of the large number of risk factors and the inclusion of minority populations. In addition, the absolute risk for CV mortality is calculated at five years for both genders, which is more accurate and clinically relevant than relative risk. The Framingham Risk Score uses BP and other risk factors to predict 5 and 10-year relative risk of cardiovascular event rate [Wilson et al. 1998 ]. This score has been adopted by the National Cholesterol Education Program in its most recent report and used to guide recommendations for the intensity of lipid-lowering therapy [National Cholesterol Education Program, 2002] .
Because the risk of CV disease is continuous and graded beginning at BP levels lower than previously targeted for treatment, the American Society of Hypertension (ASH) Hypertension Writing Group, in keeping with the previously published COSEHC guidelines, recently proposed a new working definition of hypertension that placed the levels of BP in the context of the totality of CV risk [Giles et al. 2005 ]:
1. Hypertension is a progressive CV syndrome arising from complex and interrelated etiologies. Early markers of the syndrome are often present before BP elevation is observed; therefore, hypertension cannot be classified solely by discrete BP thresholds. 2. Progression is strongly associated with functional and structural cardiac, renal, and vascular abnormalities that damage the heart, kidneys, brain, vasculature, and other organs, and lead to premature morbidity and death [Giles et al. 2005] . 3. Brachial BP readings are thus a symptom or warning of an underlying vascular and systemic condition that increases the risk of stroke, renal disease, and heart failure.
While the authors acknowledged that this definition of hypertension was a "transitional strategy" to stimulate further research and investigation into the underlying disease, the overwhelming evidence indicates a need for a new strategy and more-precise guidelines to assist physicians in the appropriate assessment of the global risk and the choices of therapy.
The more comprehensive guidelines reported by the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) stratifies cardiovascular risk both as a function of BP and the presence of concomitant factors such as the existence of the metabolic syndrome, diabetes and the clinical and laboratory assessment of target organ damage [Mancia et al. 2007b ].
There are several important implications to the evolving definition of the hypertension syndrome. The first is the recognition of increased risk in those who would previously be considered to have normal BP. At least some fraction of those with prehypertension levels of BP (120/80 mm Hg to 139/89 mm Hg) are at relatively high risk of progressing to BP levels >140/90 mm Hg and thus at future risk of end-organ damage [Elliott and Black, 2007] . Data from the Trial of Preventing Hypertension (TROPHY) study suggest that intervention with medications in those with prehypertension might change the natural history of the underlying disease process and forestall the development of overt hypertension [Julius et al. 2006] . In children and adolescences, it has been reported that prehypertension correlated with patient age, height, obesity-related diagnoses, and magnitude and frequency of abnormal blood pressure readings [Hansen et al. 2007 ].
The risks associated with elevated BP are very clear: CVD risk doubles with each 20 mm Hg increment of systolic blood pressure, beginning at levels of 115/75 mm Hg. Likewise, BP reductions and lower BP levels are associated with improved outcomes [Lewington et al. 2002; Turnbull, 2003; Williams, 2005 ]. However, if BP level is no longer the only defining characteristic of CV risk in those with hypertension, additional clinical risk markers are required to improve our ability to define, measure, and manage the underlying condition. Thus, a second important consequence of redefining hypertension will be to encourage the identification of new and better ways to measure the underlying structural and functional abnormalities involving the vascular systems that are central to the pathophysiology of hypertension. These are the "early markers" of hypertensive CV disease recognized by the Hypertension Writing Group [Giles et al. 2005] , the ESH/ESC guidelines [Mancia et al. 2007a] , and COSEHC [Bestermann et al. 2005; Houston et al. 2005] .
Structural changes in the CV system that occur in association with hypertension include increasing carotid intima-media thickness, remodeling of the small resistance vessels, and the development of left ventricular hypertrophy [Zanchetti and Waeber, 2006] . These abnormalities reflect the degree and duration of the underlying disease process [Muiesan et al. 1996; Okin et al. 2004] . Limited echocardiography has been employed successfully for many years to identify left ventricular hypertrophy and characterize risk in patients with hypertensive CV disease [Sheps and Frohlich, 1997] . Moreover, evidence suggests that regression of LVH is associated with improvement in prognosis beyond what is expected by BP reduction alone [Okin et al. 2004] . Microscopic studies showing increased wall-to-lumen ratios in arterioles correlate with increasing vascular resistance, providing a link between structure and function in vascular disease [Yu et al. 2002] . 
Review

Hypertension and hemodynamics
The hemodynamic components of mean arterial pressure and pulse pressure are shown in Figure 1 . Hemodynamic abnormalities that parallel the underlying CV changes in hypertension include changes in cardiac output, vascular resistance, fluid volume status, endothelial function, pulse wave velocity, and arterial stiffness [Freis, 2001; London and Cohn, 2002; Rossi et al. 2004; Ventura et al. 2005] . Such measurable parameters may allow for earlier determination of those at risk before the development of elevated BP or help target therapy of those with elevated BP either by guiding selection and/or intensity of antihypertensive medications.
Central aortic pressure better reflects the load imposed on the left ventricle and may provide greater information regarding efficacy of therapy than peripheral BP measurement alone [O'Rourke and Seward, 2006] . In the Conduit Artery Function Evaluation (CAFÉ) substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), central aortic pressure was derived using radial tonometry and compared between the atenolol ± thiazide and the amlodipine ± perindopril arms. Despite similar reductions in brachial BP, the calcium channel-based regimen showed a significantly greater reduction in central aortic pressure, providing a possible mechanism for the improved outcomes found in that group [Williams et al. 2006] . Similarly, studies of arterial compliance show differential effects of medications on vascular properties despite equivalent BP lowering [Resnick and Lester, 2002] .
Newer studies suggest that measurements of hemodynamic parameters may improve hypertension control. Impedance cardiography (ICG) is a noninvasive method to measure hemodynamic abnormalities that has been shown to be both accurate and reproducible [Treister et al. 2005; Van De Water et al. 2003 ]. ICG measurements have been used in hypertension to delineate the hemodynamic mechanisms of hypertension [Abdelhammed et al. 2005] , compare age-and gender-related changes in hemodynamics [Alfie et al. 1995; Galarza et al. 1997] , and detect the presence of left ventricular dysfunction [Bhalla et al. 2005] . Most importantly, two randomized controlled studies have demonstrated clinically significant improvement in BP control using ICG-guided therapy. In a single-center trial of patients with resistant hypertension treated in a hypertension specialist clinic, patients in whom therapy was guided by ICG were more likely to receive beta blockers and direct vasodilators, and to receive larger doses of diuretics. These medication differences led to more patients achieving BP control to <140/90 mm Hg (56% vs. 33%) [Taler et al. 2002] . In a multicenter trial of patients with mild-to-moderate hypertension treated in primary care settings, patients in whom therapy was guided by ICG were more likely to receive vasodilating agents when their vascular resistance was high and less likely to receive beta blockers when cardiac index was low. These medication differences led to an 8/7 mm Hg greater BP reduction, greater BP control to <140/90 mm Hg (77% vs. 57%), and greater BP control to <130/85 mm Hg (55 vs. 27%) [Smith et al. 2006] . In addition, use of ICG to control BP was shown to be cost effective in both the short-and long-term [Ferrario and Smith, 2006] . A large population-based study of the ability of hemodynamic parameters measured by ICG to define CV risk is currently underway [Chirinos, J.A. et al. 2006 ].
Other hemodynamic-based technologies measure various aspects of the hypertensive phenotype, including pulse wave analysis. Estimations of central aortic pressure and calculation of the augmentation index from the aortic waveform provide additional diagnostic and prognostic information [Izzo, Jr., 2005; Nichols, 2005; Nurnberger et al. 2002] . Analysis of the diastolic properties of the radial artery waveform allows calculation of parameters of large and small artery compliance, predictors of risk in long-term clinical studies [Cohn et al. 2005] . These noninvasive technologies provide a "totality" of functional and structural cardiovascular endpoints that arise from an infinite number of vascular risk factors, which allows the clinician to assess early vascular disease that may be missed by the conventional CV risk calculation approach. Once early vascular disease is identified, then aggressive treatment can be initiated that will reduce subsequent CV events. Despite significant progress in characterizing the hemodynamic and vascular characteristics of the hypertension syndrome, many questions remain unanswered. Can noninvasively derived hemodynamic information identify a subset of individuals with prehypertension in whom lifestyle interventions can lower risk or in whom the benefits of antihypertensive medications are justified? Can more widespread use of such measurements guide therapy more effectively than our current guidelines and achieve better outcomes?
Summary
It is clear we have room to improve how we characterize and manage patients with hypertension, particularly those with difficult-to-control hypertension. Expanded use of noninvasive hemodynamic measurements has the potential to make treatment of hypertension more targeted and more successful. This is of considerable importance as larger number of people in the developed world-economies will be predominantly above age 65. The US Department of Health and Human Services estimates showed that by the year 2030 there will be about 71.5 million older persons, more than twice the numbers in 2000 (www.aoa.gov/prof/Statistics/statistics.asp). Likewise, the European Population Reference Bureau estimates that nearly 25 percent of the European population will be above age 65 in 2030, a 17 percent increase over the 2005 numbers (www.iiasa.ac.at). The burden that is being imposed in the overall health care system and its resources in caring for the aged and the sliver of chronic diseases will require that new, cost-effective, approaches be developed. Neither new drugs nor educational programs will alone suffice in addressing these issues. We look forward to the results of future studies regarding these new measures of hemodynamic and vascular function so that we can continue to move beyond what has been achieved in the era of cuff brachial BP measurement alone.
